View in EDS HTML Full Text PDF Full Text

Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.

Saved in:
Bibliographic Details
Title: Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
Authors: Wang Z; Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Zhou Z; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China., Yang S; Department of Pediatric Urology, Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou, Guangdong, China., Zhao Z; Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China., Li X; The First Clinical College of Zhengzhou University, Zhengzhou University, Zhengzhou, China., Liu X; Department of Obstetrics and Gynecology, Xinyang Central Hospital, Xinyang, Henan, China., Cheng G; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China., Xu R; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China., Li Q; Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Xing D; Department of Emergency Intensive Care Unit (ICU), The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Source: Frontiers in immunology [Front Immunol] 2026 Jun 30; Vol. 17, pp. 1777092. Date of Electronic Publication: 2026 Jun 30 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42454028
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhou+Z%22">Zhou Z</searchLink>; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.<br /><searchLink fieldCode="AU" term="%22Yang+S%22">Yang S</searchLink>; Department of Pediatric Urology, Guangzhou Medical University Affiliated Women and Children's Medical Center, Guangzhou, Guangdong, China.<br /><searchLink fieldCode="AU" term="%22Zhao+Z%22">Zhao Z</searchLink>; Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; The First Clinical College of Zhengzhou University, Zhengzhou University, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Department of Obstetrics and Gynecology, Xinyang Central Hospital, Xinyang, Henan, China.<br /><searchLink fieldCode="AU" term="%22Cheng+G%22">Cheng G</searchLink>; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.<br /><searchLink fieldCode="AU" term="%22Xu+R%22">Xu R</searchLink>; Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Xing+D%22">Xing D</searchLink>; Department of Emergency Intensive Care Unit (ICU), The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Jun 30; Vol. 17, pp. 1777092. <i>Date of Electronic Publication: </i>2026 Jun 30 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42454028
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1777092
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1777092
    Titles:
      – TitleFull: Glycolysis-mediated H3K18la modifications drive aggressive bladder cancer through metabolic and epigenetic reprogramming.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang Z
      – PersonEntity:
          Name:
            NameFull: Zhou Z
      – PersonEntity:
          Name:
            NameFull: Yang S
      – PersonEntity:
          Name:
            NameFull: Zhao Z
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Cheng G
      – PersonEntity:
          Name:
            NameFull: Xu R
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Xing D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 30
              M: 06
              Text: 2026 Jun 30
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1